Exelixis Inc. (EXEL) had a rough trading day for Friday October 04 as shares tumbled 5.02%, or a loss of $-0.9 per share, to close at $17.04. After opening the day at $17.96, shares of Exelixis Inc. traded as high as $17.98 and as low as $16.94. Volume was 3.65 million shares over 26,237 trades, against an average daily volume of n/a shares and a total float of 302.91 million.
As a result of the decline, Exelixis Inc. now has a market cap of $5.16 billion. In the last year, shares of Exelixis Inc. have traded between a range of $25.31 and $13.42, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma.
Exelixis Inc. is based out of Alameda, CA and has some 484 employees. Its CEO is Michael M. Morrissey.
Exelixis Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.